drugset / Trial / NCT03002025

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

NCT03002025

Phase 1 Completed 48 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindOther

Summary

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) following single-dose subcutaneous (SC) injection of JNJ-64304500 in healthy Japanese male participants.

Timeline

Start
2017-01-10
Primary completion
2017-09-09
Completion
2017-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64304500 Unknown 50 mg Subcutaneous
Subject JNJ-64304500 Unknown 150 mg Subcutaneous
Subject JNJ-64304500 Unknown 400 mg Subcutaneous

Indications

No indication recorded.